Creative Biolabs is specialized in providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs of early drug discovery and development. As a trusted provider of the most cost-effective outsourcing solutions, Creative Biolabs has been working for a large number of clients from biotechnology and pharmaceutical companies as well as government and academic research laboratories all over the world. What is the company's mission? Its mission is to help researchers and scientists achieve their goals in the field of antibody related studies, by providing them with reliable products, services and customized solutions. It strives to be more than just a service provider, but a research partner that customers can rely on in exploring more in antibody study. Describe the company’s most popular service offering. Creative Biolabs has 3 main branches of services, antibody discovery, engineering and bio-manufacturing. Among them, antibody engineering services are by far the most popular offerings, such as antibody sequencing, antibody gene editing and post translational modification. Why should customers use its services? Does it save time and/or money and/or provide access to innovation? Creative Biolabs was founded by a group of scientists dedicated to the conquering of life-threatening diseases, therefore, it knows for sure about what the researchers and scientists expect from service suppliers like us. Since the establishment in 2005, it has been working for a large number of clients from biotechnology and pharmaceutical companies as well as government and academic research laboratories from over 26 countries, saving them plenty of time and money. Its scientists group always works closely with the clients. They are available for any consults about the project 24 hours a day, so as to push forward the processes smoothly. What new services, tools or technologies will it offer over the next 2 years? Antibody humanization will be its major focus in the next two years. Of course, it will also continue to expand our services in antibody discovery, engineering and bio-manufacturing. What is the company doing to remain an industry leader? Its marketing department and research team always follow closely with the biotech market especially antibody focused areas, by inviting client reviews, doing marketing researches, attending international conferences and so on. In this way, it can always know what the market is currently looking for. Besides, it’ll have one expert team follow closely with every process of each project from our clients, so as to make everything perfect. Creative Biolabs, a biotech company specialized in providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs, announces a novel strategy of manufacturing membrane protein antibodies with MagicTM Nanodiscs-based membrane protein purification service. With years of experience in membrane protein antibody production, Creative Biolabs has successfully developed MagicTM Nanodiscs-based membrane protein purification service, a comparatively new approach to manufacture membrane protein antibodies. MagicTM Nanodiscs are phospholipid bilayer membrane structures composed of membrane scaffold proteins (MSPs) and phospholipid molecules. Through this special structure, membrane protein can be integrated into MagicTM Nanodiscs, maintaining their biological activity and providing a powerful technical support for membrane protein research. This has overcome the biggest bottlenecks in membrane protein research. MagicTM Nanodiscs have sufficient and unique advantages compared with other membrane protein purification approaches. They can provide an excellent and nearly natural environment to keep membrane proteins stable. Because of their unique features, MagicTM Nanodiscs have broad application prospects. They can be applied to custom membrane protein antibody, analyze antagonists and conformational dynamics, characterize crystallization, as well as study ligand binding and protein interaction or activation. What’s more, MagicTM Nanodiscs can also be used to reconstitute membrane proteins such as GPCRs. Briefly, the MagicTM Nanodisc-solubilized proteins can be directly purified without using detergents. The completed assembly allows for the access to the physiologically intracellular and extracellular faces of the protein, which is its unique characteristic suit to G proteins and other types of protein with their own interaction partners. “We now have two methods to reconstitute membrane proteins into MagicTM Nanodiscs”, said Dr. Monika Müller, scientific officer of Creative Biolabs, “assembling the membrane proteins solubilized in the detergent and combing MagicTM Nanodiscs with cell-free expression systems”. Assemble the membrane proteins solubilized in the detergent Solubilize and purify the membrane proteins with a suitable detergent, following which membrane scaffo ld proteins and phospholipids are added into the mixture. After that, the MagicTM Nanodiscs containing the membrane proteins will assemble automatically. Combe MagicTM Nanodiscs with cell-free expression systems Express the membrane proteins in a cell-free system with the addition of pre-assembled MagicTM Nanodiscs that contains the integrated membrane proteins. In the method, the detergent is not needed. Moreover, the cell-free expression systems provide the possibility to introduce modifications into membrane proteins, such as biotinylation or isotope labelling. About Creative Biolabs Creative Biolabs is a professional service provider in developing highly specific, high affinity antibody from all popular antibody production species, including rabbit, chicken, llama, camel, alpaca, cow, dog, mouse, rat, sheep, monkey, human, and even shark. Creative Biolabs also has years of experience in developing antibody proteins. People around the entire world are been troubled by cancers for centuries, but there are few ways to treat them. Scientists have never stopped their works of finding new effective solutions. Nowadays, the rapid development of biotechnology has stepped into a new era, which creates a favorable environment where scientists and researchers can discover more usable clinical applications. Recently, some scientists have raised an idea that virus can also be used in cancer treatment, namely fighting fire with fire. What kind of items can be the “fire”? The oncolytic virus is the answer. Oncolytic virus has been regarded as a promising approach in cancer treatment. In fact, advances in the research of genetic engineering can help scientists improve the oncolytic virus, aiming at different mutation types of cancer cells. And then it can fight against the cancer in a better condition. In addition, some relevant genes’ participation can strengthen the effect of oncolytic virus. For example, the virus can carry anti-tumor genes to the appropriate places and try to enhance the capability in anti-tumor. The key of oncolytic virus is to break through the antiviral defense system of cancer cells, because only in his way can it break the resistance. During the process of releasing oncolytic virus, the tumor cells will be destroyed first and then the tumor-associated antigen will be released into the blood and recognized by the immune cells. In this way, the immunity against the tumor cells will be activated. This is the mechanism of how virus antigen leads to carcinogenic cells’ destruction. However, in practice, the anti-tumor effect of oncolytic virus, among massive tumor types, is not so consistent and efficient. Based on oncolytic virus’ shortcomings, more efforts should be done to improve the current situation. As for different development and evolution stages of oncolytic virus and tumor cells, different micro-environments such as the immune system and blood circulation system own a series of complicated connections. The applications of virus have provided a common framework to scientists, which is significant in anti-tumor research. Future research on cancer treatment may be focused on the high affinity and efficiency of the virus. 单击此处进行编辑。Antibody can be regarded as a specific protein produced in response to counteract a unique antigen that is usually used to recognize and resist the invaders. It can combine chemically with the substances that the body recognizes as outsiders such as bacteria and viruses. Thus, people can reduce the levels of that special substance through introducing it into antibody. With the immune system, antibody can release a defensive protein, including molecular markers, for research of those destroyed diseased cells.
With the rapid development of antibody technology, single domain antibody can also accomplish the same task. Because its small body is accessible to the restricted area of macromolecules much easier, single domain antibody shows a more attractive prospect. However, there are still some difficulties remained to achieve the goal, since scientists haven’t found yet an effective method to identify this kind of antibody. Fortunately, this problem has been solved by researchers from Rockefeller University. They have developed a new successful technology which can ensure that single domain antibody will significantly meet the needs of massive researching fields. The key is to find a relatively quick way to determine the gene sequence of high-affinity single domain antibody, because once those sequences are obtained, it’s easy to conduct massive production of such antibodies utilizing bacteria. Researchers first inoculate GFP and mCherry for the llamas, helping their immune system to fight against antibody of the two foreign proteins and then extracting RNA from llamas’ antibody-producing cells for the purpose of establishing an antibody sequence database. After follow-up several procedures, the most high-affinity antibody can be paired with those original RNA sequences with the help of computer program named “llama magic”. Based on this new sequence, researchers have produced 25 kinds of single domain antibody that can precisely target GFP and six kinds at mCherry with a higher efficiency. This new sequence has aroused a new inspiration. Scientists can choose the most high-affinity single domain antibody and occasionally abandon those ungraded products, declining the required amount and reducing the side effects to a better degree. In short, modern nanobody technology is able to identify high-affinity single domain antibody. A technology named "gene drive" recently attracted scientists' concern. This technology can accomplish gene mutation while two insects are copulating, passing down the "super gene" to the next generation.If terrorists take advantage of this technology, scientists warned, it is possible to produce "gene modified" insects (eg, mosquitoes) that spread deadly diseases, leading to an unprecedented environmental disaster. Theoretically, if gene drive technology is legitimately used, it can be applied to eradicate mosquito-borne diseases like malaria, yellow fever, and so on. DNA laboratory experiment The appearance of "Crispr" technology makes gene modification easier in the lab. This technology can edit the genetic code of DNA. David Gulvez, geneticist of Tel Aviv University of Israel, said that gene drive technology can accomplish gene mutation while two insects are copulating, and it is quite possible that this genetic mutation will be inherited to the next generation. The researchers compared this technology to "nuclear chain reaction that never stops," as the modified genes are inherited regardless of whether these genes are harmful to their offspring. Theoretically, if gene drive technology is legitimate used, it can be used to eradicate mosquito-borne diseases like malaria, yellow fever, and so on. However, if someone takes advantage of it with malicious purposes, the gene modified insects can be used to spread mass deadly disease. "The same as gene drive technology’s making mosquitoes no longer carry and spread malaria, the technology can also be used to modify mosquito genes so that they can carry deadly bacteria or viruses and transmit to humans", Gulvez explained. Recently, 27 well known geneticists advocated in an article published on Science that the scientific community should clarify the advantages and disadvantages of gene drive technology to people as well the disasters this technology may bring. Scientists said that "It is of great risks, and is possible to cause global disasters to human health, agricultural production and environmental protection." By drosophila experiment, scientists found that this modified super gene can be spread to almost every fruit fly of the entire breeding population only after several generations of inheritance. In 2003, Austin Bert, geneticist of Imperial College London, made a breakthrough in this theory. The appearance of "Crispr" technology which can edit the genetic code of DNA makes gene modification easier in the lab. This gene is called "super gene", because they contain a "box" genetic element that is more likely to be passed down to the next generation than normal genes. After several generations of inheritance, this gene can rapidly spread throughout the breeding population. About Monica Müller Monica Müller is the chief scientific officer of Creative Biolabs. He is an expertise of molecular biology and is mainly focused on the research and development of de novo antibody sequencing. Karolinska Institute in Stockholm awarded the 2015 Nobel Prize in Physiology or Medicine jointly to Chinese female pharmacist Youyou Tu and William C. Campbell and Satoshi Ōmura for their contributions to the research and treatment of parasitic diseases. Youyou Tu broke China’s record of "Zero Nobel" in the field of natural science. It is also the first Nobel Prize that Chinese scientists have won for their local scientific research as well as the biggest award that China has obtained so far in the medical field and traditional Chinese medicine. Youyou Tu is a 85-year-old pharmacist. She is a tenured researcher and the chief researcher of China Academy of Traditional Chinese Medicine as well as the director of the Artemisinin Research and Development Center. Engaging in traditional Chinese medicine and western medicine research for many years, Tu have made great contribution to new antimalarial— artemisinin and dihydroartemisinin. The artemisinin-based compound medicine has now become a standard treatment for malaria, which saved millions of lives all around the world, especially that of developing countries. "Artemisinin is a gift to the people of the world given by traditional Chinese medicine. It is of great significant in fighting against malaria and other infectious diseases, as well as in maintaining the health of people worldwide. The discovery of atemisinin sets an excellent example for common exploration of traditional Chinese medicine. Therefore, winning the Prize is such a great honor which shows that China’s scientific career and Chinese medicine is moving forward the whole world,” Youyou Tu said in the her testimonials. After Winning the Nobel Prize Award of 2015 Nobel Prize winner has been gradually revealed. According to regulations in the past, laureates will receive eight million kroner (950,000$) reward. How the Nobel Prize winners use the money is sometimes as original as winning the Prize itself. Professor Tu will receive half of the reward. While been about how she’s going to use it, Youyou Tu and her husband Mr. Tingzhao Li joked, "This money is not even enough to buy half of a living room in Beijing!" Dogs can help specialists "smell" cancers? It may sound impossible, yet this exploration has gained great progress. As of late, the "Cancer Sniffing Dogs Project", endorsed by the British NHS, has entered the testing stage.
Could Cancer Screening Depend Totally on Sniffing? "The proof of this testing system is that unstable molecules in tumors will go into patients' urine from dangerous cells, which give their urine a special odor. Compared to common method of identifying cancer, urine samples are easy to be collected and tested ", said Iqbal Ann, urologist of Milton Keynes University Hospital. Milton Keynes University Hospital will continue this project in the following three years. In this project, nine dogs that are trained under strict standards are going to identify urine samples from 3,000 patients, among which, there are six Labrador, two Springer Spaniel and one Hungarian Wirehaired. According to the study protocol, the cancer detection "analysis" made by these dogs will be compared to the traditional testing one, so that they can verify the accuracy of this "non-traditional" screening approach. You may have this concern that can this job be done only by one dog? According to the testing procedure, each sample will be detected by two to three dogs. If researchers can’t get the accurate results, the urine samples will be detected for the second time the next day. Can This New Testing Technology Takes Place of The Traditional One? Researchers: It can be used as the "second line of defense" in current stage at least. Prostate-specific antigen test is clinically important for prostate cancer screening. This detection, however, has its own problem that it is of high false positive rate. If the result is false-positive, patients have to accept more examinations like biopsy. Can sniffer dog detection takes the place of traditional prostate cancer screening like immunized human antibody library? It is still too early to draw a conclusion at least for now. This detection, however, has its own problem that it is of high false positive rate. If the result is false-positive, patients have to accept more examinations like biopsy. Nobody knows how to bring this brand new technology into clinical use, or whether it can be promoted widely. What researchers believe is that this detection can be utilized as a "second line of defense". After the patients have the first prostate specific antigen test, sniffer dog detection can improve the accuracy of cancer screening. DNA immunization is a technique for protecting an organism against disease by injecting it with genetically engineered DNA to produce an immunological response. It has a number of advantages over conventional immunization, including the ability to induce a wider range of immune response types.
DNA immunization, also known as gene immunization, polynucleotide vaccine and DNA vaccine, is a newly established immunological theory and technique first discovered in the 1990s. Compared with current protein vaccine, DNA immunization is safer and more inexpensive. Besides, it induces a more effective immune response and is easy to be prepared. With the potential application in some specific field, DNA immunization is not only been widely used in anti-virus, bacteria, fungi, parasites as well as other anti-infection immunity, but also plays a n important role in tumor immunology and autoimmune disease. Like all other groups, Creative Biolabs follows up with the updated technique in DNA immunization, and made their own innovation by putting DNA immunization in the production of antibody. Creative BioLabs has developed Direct Antibody Technology™ (DAT) to produce custom polyclonal and monoclonal antibodies. As a highly optimized service, this DNA immunization technology relies on a proprietary genetic immunization procedure using plasmid DNA encoding the target protein of interest. The immunized hosts then produce the encoded protein and raise antibodies in vivo. To ensure the accomplishment of the genetic immunization, the cDNA-encoded protein must be secreted by the transfected cells in immunized animals or expressed on the surface of the transfected cells. Creative BioLabs introduces the gene in the form of a cDNA directly into an animal, which translates this cDNA into protein thus stimulating an immune response against the foreign protein. As a result, synthesis and purification of protein immunogens is not necessary for this genetic immunization approach. Creative BioLabs’ Direct Antibody Technology™ maximizes the likelihood of producing and maintaining the native structure of the antigen. The foremost advantage of this antibody production approach is its high success rate in generation of high-affinity antibodies recognizing membrane proteins (such as 7-membrane-spanning GPCR proteins, ion channels and other multiple membrane spanning proteins) in their native conformation, unknown proteins whose genes have been obtained, toxic proteins, insoluble proteins, proteins containing disulfide bonds, post-translational modified proteins, or large protein domains. For therapeutic antibodies, however, the antigens in their native conformation should be targeted with a high-affinity. Creative Biolabs is a leading service provider in the field of DNA immunization. For reliable, accurate and cost effective DNA immunization services, please visit creative-biolabs.com. Fragment antibody-binding (Fab fragment) is a region on an antibody that binds to antigens. It is composed of one constant and one variable domain of each of the heavy and the light chain. Single-chain variable fragment (scFv) is not actually a fragment of an antibody, but instead is a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of immunoglobulins, connected with a short linker peptide of ten to about 25 amino acids. Fab fragments differ from scFv's as they contain both variable domains and constant regions, thus are more complex in construction and ultimate expression. Creative Biolabs is an expert with many years of experiences in antibody production. It has established a solid platform for scFv and Fab constuction. The same heavy and light variable chains used for scFv construction can also be used in the construction of Fab. There are three routes to have a scFv or Fab target a specific antigen in Creative Biolabs. The first approach is to generate a mouse hybridoma clone, then convert full IgG [or IgM] into a scFv or Fab; the second one is to create an immunized phage display scFv or Fab mouse library, then use the antigen to screen the library; the third method is to use the antigen to screen a premade scFv or Fab antibody phage display library [usually a human one] to get scFv or Fab clones directly. We are also able to convert chicken IgY into scFv or Fab fragments. In Creative Biolabs, customers will experience professional and high-qualified scFv/Fab Construction services. To learn more about the procedures, please visit here. |
Archives
November 2016
Categories |